Roberto Bizzotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Roberto Bizzotto has a total of 446 co-authors. Here are the top co-authors by number of shared publications:
Andrea Mari
Institute of Neuroscience–National Research Council , 35127 Padua , Italy
11 shared publications- Andrea Mari
Institute of Neuroscience, National Research Council, Padova, Italy
7 shared publications - Ele Ferrannini
CNR Institute of Clinical Physiology, Pisa, Italy
4 shared publications Alex Gonzalez
Behavioral Medicine Research Center, University of Miami, Miami, FL, USA
3 shared publications- Andrea Natali
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
3 shared publications Andrea Tura
C.N.R. Institute of Neuroscience, Padova, Italy
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Pancreatic fat and stiffness reflect distinct features of pancreatic remodeling and β-cell function
Context: Fatty pancreas is associated with obesity and metabolic alterations and may coexist with pancreatic structural remodeling. However, its contribution to β-cell dysfunction remains unclear. Objective: We investigated the relationship between pancreatic fat, tissue remodeling, and β-cell function. Design: We conducted a cross-sectional study in individuals with ultrasound-detected pancreatic hyperechogenicity without prior diagnosis of diabetes. Pancreatic fat was quantified by magnetic resonance imaging (MRI)-derived proton density fat fraction, while tissue stiffness was assessed by shear wave elastography. Metabolic phenotyping was based on oral glucose tolerance test (OGTT). Participants: We recruited 29 individuals with ultrasound-detected fatty pancreas (F/M 16/13, age 54 ± 10.4 years) and assessed glucose tolerance with OGTT: 75.9% exhibited normal glucose tolerance (n = 22), while 24.1% had impaired glucose tolerance (n = 7). Results: MRI-derived pancreatic fat fraction was positively correlated with anthropometric measures (body mass index ρ = 0.43, P = .02) and β-cell function (β-cell glucose sensitivity ρ = 0.40, P = .03). Pancreatic stiffness correlated negatively with body weight (ρ = −0.38, P = .04), did not correlate with pancreatic fat fraction (ρ = −0.15, P = .44), and was correlated inversely with the potentiation factor ratio 1 (ρ = −0.44, P = .02), a measure of non–glucose-dependent amplification of insulin secretion. Conclusion: Intrapancreatic fat and pancreatic stiffness appear to reflect distinct pathophysiological processes, with potentially different relationships to systemic metabolic status and β-cell function. These findings support a more nuanced view of pancreatic structural alterations as heterogeneous markers of metabolic dysfunction.
- 29 September 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessPancreatic fat and stiffness reflect distinct features of pancreatic remodeling and β-cell function
Context: Fatty pancreas is associated with obesity and metabolic alterations and may coexist with pancreatic structural remodeling. However, its contribution to β-cell dysfunction remains unclear. Objective: We investigated the relationship between pancreatic fat, tissue remodeling, and β-cell function. Design: We conducted a cross-sectional study in individuals with ultrasound-detected pancreatic hyperechogenicity without prior diagnosis of diabetes. Pancreatic fat was quantified by magnetic resonance imaging (MRI)-derived proton density fat fraction, while tissue stiffness was assessed by shear wave elastography. Metabolic phenotyping was based on oral glucose tolerance test (OGTT). Participants: We recruited 29 individuals with ultrasound-detected fatty pancreas (F/M 16/13, age 54 ± 10.4 years) and assessed glucose tolerance with OGTT: 75.9% exhibited normal glucose tolerance (n = 22), while 24.1% had impaired glucose tolerance (n = 7). Results: MRI-derived pancreatic fat fraction was positively correlated with anthropometric measures (body mass index ρ = 0.43, P = .02) and β-cell function (β-cell glucose sensitivity ρ = 0.40, P = .03). Pancreatic stiffness correlated negatively with body weight (ρ = −0.38, P = .04), did not correlate with pancreatic fat fraction (ρ = −0.15, P = .44), and was correlated inversely with the potentiation factor ratio 1 (ρ = −0.44, P = .02), a measure of non–glucose-dependent amplification of insulin secretion. Conclusion: Intrapancreatic fat and pancreatic stiffness appear to reflect distinct pathophysiological processes, with potentially different relationships to systemic metabolic status and β-cell function. These findings support a more nuanced view of pancreatic structural alterations as heterogeneous markers of metabolic dysfunction.
- 6 June 2026
- Published by Springer Nature in Diabetologia
Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages
Type 2 diabetes mellitus is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable circulating biomarkers are currently available to track this decline. As microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs reflect in vivo beta cell function in living donors. We conducted a cross-sectional study on two independent cohorts: a discovery cohort comprising 78 individuals with different levels of glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT) and 33 with type 2 diabetes] and a validation cohort comprising 158 individuals (71 non-diabetic individuals and 87 with type 2 diabetes) who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. We profiled plasma RNA by small RNA sequencing, and analysed differences between glucose tolerance groups using DESeq2. We used linear regression analyses to determine the association between miRNA abundance and clinical and metabolic measures. We validated selected miRNAs using droplet digital PCR (ddPCR). Finally, we specified a set of features that were used as an input for a LASSO model to select a biomarker signature that was able to estimate beta cell rate sensitivity (RS) values as a measure of beta cell function. We identified 11 miRNAs that were differentially expressed across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNA signature (miR-34a-5p, miR-1306-5p and miR-335-5p) that correlated with beta cell RS, which is an early indicator of insulin secretory impairment. We incorporated this panel of selected miRNAs with age and 1 h post-load glucose into a LASSO regression model that enabled discrimination of RS values (Spearman's ρ=0.43, p<0.05). We also confirmed model performance in an additional cohort of 71 non-diabetic individuals and 87 individuals with type 2 diabetes (Spearman's ρ=0.23, p<0.05). To provide proof of concept for potential clinical use, we substituted basal glucose for 1 h post-load glucose while retaining miRNA levels and age; this adaptation preserved the significance of the model in the discovery cohort (Spearman's ρ=0.46, p<0.05), and showed an interesting, but not significant, association in the validation cohort (Spearman's ρ=0.15, p=0.061). This three-miRNA signature combined with simple clinical parameters constitutes a promising biomarker for early beta cell dysfunction and type 2 diabetes progression that deserves further validation in additional cohorts.
- 6 June 2026
- Published by Springer Nature in Diabetologia
Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages
Type 2 diabetes mellitus is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable circulating biomarkers are currently available to track this decline. As microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs reflect in vivo beta cell function in living donors. We conducted a cross-sectional study on two independent cohorts: a discovery cohort comprising 78 individuals with different levels of glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT) and 33 with type 2 diabetes] and a validation cohort comprising 158 individuals (71 non-diabetic individuals and 87 with type 2 diabetes) who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. We profiled plasma RNA by small RNA sequencing, and analysed differences between glucose tolerance groups using DESeq2. We used linear regression analyses to determine the association between miRNA abundance and clinical and metabolic measures. We validated selected miRNAs using droplet digital PCR (ddPCR). Finally, we specified a set of features that were used as an input for a LASSO model to select a biomarker signature that was able to estimate beta cell rate sensitivity (RS) values as a measure of beta cell function. We identified 11 miRNAs that were differentially expressed across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNA signature (miR-34a-5p, miR-1306-5p and miR-335-5p) that correlated with beta cell RS, which is an early indicator of insulin secretory impairment. We incorporated this panel of selected miRNAs with age and 1 h post-load glucose into a LASSO regression model that enabled discrimination of RS values (Spearman's ρ=0.43, p<0.05). We also confirmed model performance in an additional cohort of 71 non-diabetic individuals and 87 individuals with type 2 diabetes (Spearman's ρ=0.23, p<0.05). To provide proof of concept for potential clinical use, we substituted basal glucose for 1 h post-load glucose while retaining miRNA levels and age; this adaptation preserved the significance of the model in the discovery cohort (Spearman's ρ=0.46, p<0.05), and showed an interesting, but not significant, association in the validation cohort (Spearman's ρ=0.15, p=0.061). This three-miRNA signature combined with simple clinical parameters constitutes a promising biomarker for early beta cell dysfunction and type 2 diabetes progression that deserves further validation in additional cohorts.
- Open Access
- 21 April 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (7) , 2073-2087
Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease
Aims/hypothesis: Hepatic glucose flux plays a crucial role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), promoting de novo lipogenesis, inflammation and fibrosis. This study aimed to evaluate the kinetics of oral glucose absorption and one of its key modulators, gastric emptying, in individuals with early-stage MASLD vs matched control individuals. Methods: We quantified glucose metabolic fluxes during a 75 g OGTT using stable isotopes in individuals with MASLD without fibrosis and in healthy control individuals. In a separate cohort, we measured the gastric emptying rate using the 13 C-acetate breath test during an OGTT and estimated hepatic steatosis risk. Results: Compared with the control group, in the MASLD group the rate of appearance of oral ingested glucose (RaO) normalised to body weight was 34% higher at 1 h post-OGTT (+318±142 µmol/kg, p =0.031), resulting in a 52% increase in total glucose absorption (+6.4±1.8 g, p =0.001). Participants with MASLD exhibited reduced glucose clearance relative to plasma insulin levels but preserved post-load suppression of endogenous glucose production, indicating peripheral rather than hepatic insulin resistance. Among glucose metabolic fluxes, RaO showed the strongest association with prevalent MASLD, with each 1-SD increase in 1 h RaO being associated with fivefold higher odds of MASLD (OR 4.99 [95% CI 1.44, 31.57], p =0.036), independent of potential confounders. Gastric emptying rate was not associated with hepatic steatosis risk. Conclusions/interpretation: Oral glucose absorption is augmented in individuals with MASLD without fibrosis, apparently unrelated to accelerated gastric emptying. This metabolic alteration may represent an early driver of MASLD pathogenesis, preceding hepatic insulin resistance. Future research should investigate whether modulation of intestinal glucose absorption confers therapeutic benefits in MASLD.
- 21 April 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (7) , 2073-2087
Open AccessOral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease
Aims/hypothesis: Hepatic glucose flux plays a crucial role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), promoting de novo lipogenesis, inflammation and fibrosis. This study aimed to evaluate the kinetics of oral glucose absorption and one of its key modulators, gastric emptying, in individuals with early-stage MASLD vs matched control individuals. Methods: We quantified glucose metabolic fluxes during a 75 g OGTT using stable isotopes in individuals with MASLD without fibrosis and in healthy control individuals. In a separate cohort, we measured the gastric emptying rate using the 13 C-acetate breath test during an OGTT and estimated hepatic steatosis risk. Results: Compared with the control group, in the MASLD group the rate of appearance of oral ingested glucose (RaO) normalised to body weight was 34% higher at 1 h post-OGTT (+318±142 µmol/kg, p =0.031), resulting in a 52% increase in total glucose absorption (+6.4±1.8 g, p =0.001). Participants with MASLD exhibited reduced glucose clearance relative to plasma insulin levels but preserved post-load suppression of endogenous glucose production, indicating peripheral rather than hepatic insulin resistance. Among glucose metabolic fluxes, RaO showed the strongest association with prevalent MASLD, with each 1-SD increase in 1 h RaO being associated with fivefold higher odds of MASLD (OR 4.99 [95% CI 1.44, 31.57], p =0.036), independent of potential confounders. Gastric emptying rate was not associated with hepatic steatosis risk. Conclusions/interpretation: Oral glucose absorption is augmented in individuals with MASLD without fibrosis, apparently unrelated to accelerated gastric emptying. This metabolic alteration may represent an early driver of MASLD pathogenesis, preceding hepatic insulin resistance. Future research should investigate whether modulation of intestinal glucose absorption confers therapeutic benefits in MASLD.
- Open Access
Plasma Small RNA profiling reveals a predictive three-miRNAs signature for early beta cell dysfunction across glucose tolerance stages
Aims/hypothesis: Type 2 diabetes mellitus (T2D) is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable and non-invasive circulating biomarkers are currently available to track this decline. Since microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs may reflect in vivo beta cell function in living donors. Methods: We conducted a cross-sectional study on two independent cohorts: a discovery cohort composed by 78 individuals with different glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT), and 33 with T2D] and a validation cohort composed by 158 subjects [71 non-diabetic (ND) and 87 with T2D] who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. Plasma RNA was profiled by small RNA sequencing and differences between glucose tolerance groups were analysed using DESeq2. Linear regression analyses were used to associate miRNA abundance to clinical and metabolic measures. Droplet Digital PCR (ddPCR) was used to validate selected miRNAs. A LASSO model was used to select a set of features predictive of beta cell function. Results: We identified eleven differentially expressed miRNAs across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNAs signature (miR-34a-5p, miR-1306-5p and miR-335-5p) each significantly correlated with beta cell rate sensitivity (RS), an early indicator of insulin secretory impairment. Incorporating this panel with age and 1-hour post-load glucose into a LASSO regression model enabled accurate prediction of RS (Spearman ρ=0.43, p<0.05). Model performance was confirmed in the validation cohort of 71 ND and 87 T2D subjects (Spearman ρ=0.23, p<0.05). To streamline its clinical use, we substituted fasting glucose for 1-hour post-load glucose while retaining miRNA levels and age; this adaptation preserved predictive power (Spearman ρ=0.46, p<0.05 discovery; ρ=0.15, p=0.06 validation). Conclusion/interpretation: This three-miRNAs signature combined with simple clinical parameters constitutes a promising, non-invasive biomarker for early beta cell dysfunction and T2D progression. Research in context: What is already known about this subject?: Beta cell dysfunction is a key event in Type 2 Diabetes (T2D) pathogenesis Circulating microRNAs (miRNAs) are biomarkers linked to T2D onset and T2D-associated metabolic abnormalities What is the key question?: Can specific circulating miRNAs serve as reliable biomarkers of beta cell dysfunction across different stages of glucose tolerance and Type 2 Diabetes (T2D)? What are the new findings?: Small RNA profiling of plasma samples from deep metabolically characterized NGT, IGT, and T2D subjects revealed circulating miRNAs significantly associated with in-vivo beta cell function, reflecting key mechanisms underlying pancreatic beta cell physiology A specific set of three circulating miRNAs- miR-34a-5p, miR-1306-5p and miR-335-5p - resulted linked to beta cell dysfunction This three-miRNA signature can predict early alterations in insulin secretion, representing a promising non-invasive biomarker for the early identification of individuals at risk of developing T2D How might this impact on clinical practice in the foreseeable future?: Integrating circulating miRNA profiling with routine baseline clinical parameters could provide a simpler, non-invasive, and more accessible method to identify individuals at risk of beta cell dysfunction and T2D. Implementing miRNA-based diagnostics could facilitate personalized monitoring of disease progression. Graphical
Open AccessPlasma Small RNA profiling reveals a predictive three-miRNAs signature for early beta cell dysfunction across glucose tolerance stages
Aims/hypothesis: Type 2 diabetes mellitus (T2D) is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable and non-invasive circulating biomarkers are currently available to track this decline. Since microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs may reflect in vivo beta cell function in living donors. Methods: We conducted a cross-sectional study on two independent cohorts: a discovery cohort composed by 78 individuals with different glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT), and 33 with T2D] and a validation cohort composed by 158 subjects [71 non-diabetic (ND) and 87 with T2D] who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. Plasma RNA was profiled by small RNA sequencing and differences between glucose tolerance groups were analysed using DESeq2. Linear regression analyses were used to associate miRNA abundance to clinical and metabolic measures. Droplet Digital PCR (ddPCR) was used to validate selected miRNAs. A LASSO model was used to select a set of features predictive of beta cell function. Results: We identified eleven differentially expressed miRNAs across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNAs signature (miR-34a-5p, miR-1306-5p and miR-335-5p) each significantly correlated with beta cell rate sensitivity (RS), an early indicator of insulin secretory impairment. Incorporating this panel with age and 1-hour post-load glucose into a LASSO regression model enabled accurate prediction of RS (Spearman ρ=0.43, p<0.05). Model performance was confirmed in the validation cohort of 71 ND and 87 T2D subjects (Spearman ρ=0.23, p<0.05). To streamline its clinical use, we substituted fasting glucose for 1-hour post-load glucose while retaining miRNA levels and age; this adaptation preserved predictive power (Spearman ρ=0.46, p<0.05 discovery; ρ=0.15, p=0.06 validation). Conclusion/interpretation: This three-miRNAs signature combined with simple clinical parameters constitutes a promising, non-invasive biomarker for early beta cell dysfunction and T2D progression. Research in context: What is already known about this subject?: Beta cell dysfunction is a key event in Type 2 Diabetes (T2D) pathogenesis Circulating microRNAs (miRNAs) are biomarkers linked to T2D onset and T2D-associated metabolic abnormalities What is the key question?: Can specific circulating miRNAs serve as reliable biomarkers of beta cell dysfunction across different stages of glucose tolerance and Type 2 Diabetes (T2D)? What are the new findings?: Small RNA profiling of plasma samples from deep metabolically characterized NGT, IGT, and T2D subjects revealed circulating miRNAs significantly associated with in-vivo beta cell function, reflecting key mechanisms underlying pancreatic beta cell physiology A specific set of three circulating miRNAs- miR-34a-5p, miR-1306-5p and miR-335-5p - resulted linked to beta cell dysfunction This three-miRNA signature can predict early alterations in insulin secretion, representing a promising non-invasive biomarker for the early identification of individuals at risk of developing T2D How might this impact on clinical practice in the foreseeable future?: Integrating circulating miRNA profiling with routine baseline clinical parameters could provide a simpler, non-invasive, and more accessible method to identify individuals at risk of beta cell dysfunction and T2D. Implementing miRNA-based diagnostics could facilitate personalized monitoring of disease progression. Graphical
- Open Access
- 30 April 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (9) , e1697-e1707
The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study
Context: The role of glucagon-like peptide-1 (GLP-1) in type 2 diabetes (T2D) and obesity is not fully understood. Objective: We investigate the association of cardiometabolic, diet, and lifestyle parameters on fasting and postprandial GLP-1 in people at risk of, or living with, T2D. Methods: We analyzed cross-sectional data from the two Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) cohorts, cohort 1 (n = 2127) individuals at risk of diabetes; cohort 2 (n = 789) individuals with new-onset T2D. Results: Our multiple regression analysis reveals that fasting total GLP-1 is associated with an insulin-resistant phenotype and observe a strong independent relationship with male sex, increased adiposity, and liver fat, particularly in the prediabetes population. In contrast, we showed that incremental GLP-1 decreases with worsening glycemia, higher adiposity, liver fat, male sex, and reduced insulin sensitivity in the prediabetes cohort. Higher fasting total GLP-1 was associated with a low intake of wholegrain, fruit, and vegetables in people with prediabetes, and with a high intake of red meat and alcohol in people with diabetes. Conclusion: These studies provide novel insights into the association between fasting and incremental GLP-1, metabolic traits of diabetes and obesity, and dietary intake, and raise intriguing questions regarding the relevance of fasting GLP-1 in the pathophysiology T2D.
- 30 April 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (9) , e1697-e1707
Open AccessThe Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study
Context: The role of glucagon-like peptide-1 (GLP-1) in type 2 diabetes (T2D) and obesity is not fully understood. Objective: We investigate the association of cardiometabolic, diet, and lifestyle parameters on fasting and postprandial GLP-1 in people at risk of, or living with, T2D. Methods: We analyzed cross-sectional data from the two Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) cohorts, cohort 1 (n = 2127) individuals at risk of diabetes; cohort 2 (n = 789) individuals with new-onset T2D. Results: Our multiple regression analysis reveals that fasting total GLP-1 is associated with an insulin-resistant phenotype and observe a strong independent relationship with male sex, increased adiposity, and liver fat, particularly in the prediabetes population. In contrast, we showed that incremental GLP-1 decreases with worsening glycemia, higher adiposity, liver fat, male sex, and reduced insulin sensitivity in the prediabetes cohort. Higher fasting total GLP-1 was associated with a low intake of wholegrain, fruit, and vegetables in people with prediabetes, and with a high intake of red meat and alcohol in people with diabetes. Conclusion: These studies provide novel insights into the association between fasting and incremental GLP-1, metabolic traits of diabetes and obesity, and dietary intake, and raise intriguing questions regarding the relevance of fasting GLP-1 in the pathophysiology T2D.
- 31 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , 461-470
At any Level of Adiposity, Relatively Elevated Leptin Concentrations Are Associated With Decreased Insulin Sensitivity
Context The impact of obesity on glucose homeostasis has a high interindividual variability, which may be partially explained by different adipokines concentrations. Leptin regulates energy balance and metabolism, and although its plasma levels are proportional to fat mass, they vary significantly across individuals with the same level of adiposity. Objective We tested whether glucose homeostasis differs in subjects with similar degrees of adiposity but different leptin levels. Methods We analyzed 1,290 healthy adults from the RISC study cohort (30-60 years, M/F 577/713, BMI 25 ± 3 kg/m2) characterized for body composition and metabolic variables with a 75-g OGTT, euglycemic-hyperinsulinemic clamp, β-cell function and lipidomics. Results Individuals were divided into relatively high and low leptin (RHL and RLL) if they were above or below the sex-specific leptin-fat mass(%) regression. Despite similar glucose tolerance, RHL showed markedly higher fasting and OGTT insulin concentration (+30% and +29% respectively, p < 0.0001) and secretion (+17% and +11% respectively, p < 0.0001). Regardless of BMI, RHL individuals had lower whole-body (-17-23%, p < 0.0001) and adipose tissue insulin sensitivity (-24%, p < 0.0001) compared to RLL. Notably, lean RHL individuals showed similar insulin sensitivity and β-cell function to RLL individuals with overweight/obesity. Conclusion Subjects with leptin levels that are inappropriately elevated for their fat mass show whole-body/adipose tissue insulin resistance and hyperinsulinemia, regardless of BMI.
- 31 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , 461-470
At any Level of Adiposity, Relatively Elevated Leptin Concentrations Are Associated With Decreased Insulin Sensitivity
Context The impact of obesity on glucose homeostasis has a high interindividual variability, which may be partially explained by different adipokines concentrations. Leptin regulates energy balance and metabolism, and although its plasma levels are proportional to fat mass, they vary significantly across individuals with the same level of adiposity. Objective We tested whether glucose homeostasis differs in subjects with similar degrees of adiposity but different leptin levels. Methods We analyzed 1,290 healthy adults from the RISC study cohort (30-60 years, M/F 577/713, BMI 25 ± 3 kg/m2) characterized for body composition and metabolic variables with a 75-g OGTT, euglycemic-hyperinsulinemic clamp, β-cell function and lipidomics. Results Individuals were divided into relatively high and low leptin (RHL and RLL) if they were above or below the sex-specific leptin-fat mass(%) regression. Despite similar glucose tolerance, RHL showed markedly higher fasting and OGTT insulin concentration (+30% and +29% respectively, p < 0.0001) and secretion (+17% and +11% respectively, p < 0.0001). Regardless of BMI, RHL individuals had lower whole-body (-17-23%, p < 0.0001) and adipose tissue insulin sensitivity (-24%, p < 0.0001) compared to RLL. Notably, lean RHL individuals showed similar insulin sensitivity and β-cell function to RLL individuals with overweight/obesity. Conclusion Subjects with leptin levels that are inappropriately elevated for their fat mass show whole-body/adipose tissue insulin resistance and hyperinsulinemia, regardless of BMI.
- 1 February 2022
- Published by Elsevier in Veterinary Anaesthesia and Analgesia
- Vol. 50 (1) , 31-40
Development and optimization of a fentanyl pharmacokinetic model for target-controlled infusion in anaesthetized dogs
- 1 February 2022
- Published by Elsevier in Veterinary Anaesthesia and Analgesia
- Vol. 50 (1) , 31-40
Development and optimization of a fentanyl pharmacokinetic model for target-controlled infusion in anaesthetized dogs
- Open Access
- 4 January 2022
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (1) , 100477
Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study
- 4 January 2022
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (1) , 100477
Open AccessFour groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study
- 26 August 2021
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (9) , 2115-2123
New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms
OBJECTIVE: Endogenous insulin clearance (EIC) is physiologically reduced at increasing insulin secretion rate (ISR). Computing EIC at the prevailing ISR does not distinguish the effects of hypersecretion from those of other mechanisms of glucose homeostasis. We aimed to measure EIC in standardized ISR conditions (i.e., at fixed ISR levels) and to analyze its associations with relevant physiologic factors. RESEARCH DESIGN AND METHODS: We estimated standardized EIC (EICISR) by mathematical modeling in nine different studies with insulin and glucose infusions (N = 2,067). EICISR association with various traits was analyzed by stepwise multivariable regression in studies with both euglycemic clamp and oral glucose tolerance test (OGTT) (N = 1,410). We also tested whether oral glucose ingestion, as opposed to intravenous infusion, has an independent effect on EIC (N = 1,555). RESULTS: Insulin sensitivity (as M/I from the euglycemic clamp) is the strongest determinant of EICISR, approximately four times more influential than insulin resistance–related hypersecretion. EICISR independently associates positively with M/I, fasting and mean OGTT glucose or type 2 diabetes, and β-cell glucose sensitivity and negatively with African American or Hispanic race, female sex, and female age. With oral glucose ingestion, an ISR-independent ∼10% EIC reduction is necessary to explain the observed insulin concentration profiles. CONCLUSIONS: Based on EICISR, we posit the existence of two adaptive processes involving insulin clearance: the first reduces EICISR with insulin resistance (not with higher BMI per se) and is more relevant than the concomitant hypersecretion; the second reduces EICISR with β-cell dysfunction. These processes are dysregulated in type 2 diabetes. Finally, oral glucose ingestion per se reduces insulin clearance.
- 26 August 2021
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (9) , 2115-2123
New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms
OBJECTIVE: Endogenous insulin clearance (EIC) is physiologically reduced at increasing insulin secretion rate (ISR). Computing EIC at the prevailing ISR does not distinguish the effects of hypersecretion from those of other mechanisms of glucose homeostasis. We aimed to measure EIC in standardized ISR conditions (i.e., at fixed ISR levels) and to analyze its associations with relevant physiologic factors. RESEARCH DESIGN AND METHODS: We estimated standardized EIC (EICISR) by mathematical modeling in nine different studies with insulin and glucose infusions (N = 2,067). EICISR association with various traits was analyzed by stepwise multivariable regression in studies with both euglycemic clamp and oral glucose tolerance test (OGTT) (N = 1,410). We also tested whether oral glucose ingestion, as opposed to intravenous infusion, has an independent effect on EIC (N = 1,555). RESULTS: Insulin sensitivity (as M/I from the euglycemic clamp) is the strongest determinant of EICISR, approximately four times more influential than insulin resistance–related hypersecretion. EICISR independently associates positively with M/I, fasting and mean OGTT glucose or type 2 diabetes, and β-cell glucose sensitivity and negatively with African American or Hispanic race, female sex, and female age. With oral glucose ingestion, an ISR-independent ∼10% EIC reduction is necessary to explain the observed insulin concentration profiles. CONCLUSIONS: Based on EICISR, we posit the existence of two adaptive processes involving insulin clearance: the first reduces EICISR with insulin resistance (not with higher BMI per se) and is more relevant than the concomitant hypersecretion; the second reduces EICISR with β-cell dysfunction. These processes are dysregulated in type 2 diabetes. Finally, oral glucose ingestion per se reduces insulin clearance.
- 15 December 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (2) , 511-518
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
OBJECTIVE We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS A total of 732 recently diagnosed patients with T2D from the Innovative Medicines Initiative Diabetes Research on Patient Stratification (IMI DIRECT) study were extensively phenotyped over 3 years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS), and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise multivariable linear and logistic regression. RESULTS Faster HbA1c progression was independently associated with faster deterioration of OGIS and GS and increasing CLIm; visceral or liver fat, HDL-cholesterol, and triglycerides had further independent, though weaker, roles (R2 = 0.38). A subgroup of patients with a markedly higher progression rate (fast progressors) was clearly distinguishable considering these variables only (discrimination capacity from area under the receiver operating characteristic = 0.94). The proportion of fast progressors was reduced from 56% to 8–10% in subgroups in which only one trait among OGIS, GS, and CLIm was relatively stable (odds ratios 0.07–0.09). T2D polygenic risk score and baseline pancreatic fat, glucagon-like peptide 1, glucagon, diet, and physical activity did not show an independent role. CONCLUSIONS Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration of patients with T2D in the initial phase of the disease. Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression.
- 15 December 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (2) , 511-518
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
OBJECTIVE We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS A total of 732 recently diagnosed patients with T2D from the Innovative Medicines Initiative Diabetes Research on Patient Stratification (IMI DIRECT) study were extensively phenotyped over 3 years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS), and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise multivariable linear and logistic regression. RESULTS Faster HbA1c progression was independently associated with faster deterioration of OGIS and GS and increasing CLIm; visceral or liver fat, HDL-cholesterol, and triglycerides had further independent, though weaker, roles (R2 = 0.38). A subgroup of patients with a markedly higher progression rate (fast progressors) was clearly distinguishable considering these variables only (discrimination capacity from area under the receiver operating characteristic = 0.94). The proportion of fast progressors was reduced from 56% to 8–10% in subgroups in which only one trait among OGIS, GS, and CLIm was relatively stable (odds ratios 0.07–0.09). T2D polygenic risk score and baseline pancreatic fat, glucagon-like peptide 1, glucagon, diet, and physical activity did not show an independent role. CONCLUSIONS Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration of patients with T2D in the initial phase of the disease. Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression.